Arrythmias Are a Significant Comorbidity in Adult Congenital Heart Disease
By Elana Gotkine HealthDay Reporter
WEDNESDAY, April 17, 2024 -- For patients with adult congenital heart disease, arrythmias are a significant comorbidity and are associated with health care use and increased mortality, according to a study published online April 17 in the Journal of the American Heart Association.
Nili Schamroth Pravda, M.B.B,Ch., from the Rabin Medical Center in Petach Tikva, Israel, and colleagues examined arrhythmia prevalence, risk factors, and associated health care use in a cohort of 11,653 patients with adult congenital heart disease.
The researchers found that at baseline, 8.7 percent of the patients had tachyarrhythmia, 1.5 percent had a conduction disturbance, and 0.5 percent had both. Of those without a baseline arrhythmia, 9.2, 0.9, and 0.3 percent developed tachyarrhythmias, a conduction disturbance, and both, respectively, during the study period between January 2007 and December 2011. Arrhythmia in the previous six months was associated with higher multivariable adjusted hospitalization rates, which were 1.33-, 1.27-, and 1.33-fold higher for ventricular arrythmia, atrial arrhythmias, and atrioventricular block, respectively, compared with the reference group. The adjusted hazard ratio for mortality was 1.65 and 2.06 in association with atrial tachyarrhythmias and ventricular tachyarrhythmias, respectively.
"Arrhythmias are common comorbidities in the adult congenital heart disease population and have a significant impact on health care usage and survival," the authors write. "This should be taken into consideration in this population in which lifelong follow-up is needed."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD
WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.